176 related articles for article (PubMed ID: 32283296)
1. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
Dalle Vedove A; Zonta F; Zanforlin E; Demitri N; Ribaudo G; Cazzanelli G; Ongaro A; Sarno S; Zagotto G; Battistutta R; Ruzzene M; Lolli G
Eur J Med Chem; 2020 Jun; 195():112267. PubMed ID: 32283296
[TBL] [Abstract][Full Text] [Related]
2. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice.
Morooka S; Hoshina M; Kii I; Okabe T; Kojima H; Inoue N; Okuno Y; Denawa M; Yoshida S; Fukuhara J; Ninomiya K; Ikura T; Furuya T; Nagano T; Noda K; Ishida S; Hosoya T; Ito N; Yoshimura N; Hagiwara M
Mol Pharmacol; 2015 Aug; 88(2):316-25. PubMed ID: 25993998
[TBL] [Abstract][Full Text] [Related]
4. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.
Protopopov MV; Ostrynska OV; Starosyla SA; Vodolazhenko MA; Sirko SM; Gorobets NY; Bdzhola V; Desenko SM; Yarmoluk SM
Mol Divers; 2018 Nov; 22(4):991-998. PubMed ID: 29845490
[TBL] [Abstract][Full Text] [Related]
5. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
6. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
7. Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.
Krämer A; Kurz CG; Berger BT; Celik IE; Tjaden A; Greco FA; Knapp S; Hanke T
Eur J Med Chem; 2020 Dec; 208():112770. PubMed ID: 32883634
[TBL] [Abstract][Full Text] [Related]
8. A Note of Caution on the Role of Halogen Bonds for Protein Kinase/Inhibitor Recognition Suggested by High- And Low-Salt CK2α Complex Structures.
Guerra B; Bischoff N; Bdzhola VG; Yarmoluk SM; Issinger OG; Golub AG; Niefind K
ACS Chem Biol; 2015 Jul; 10(7):1654-60. PubMed ID: 25961323
[TBL] [Abstract][Full Text] [Related]
9. An overview about the impact of hinge region towards the anticancer binding affinity of the Ck2 ligands: a quantum chemical analysis.
Deepa P; Thirumeignanam D; Kolandaivel P
J Biomol Struct Dyn; 2019 Sep; 37(15):3859-3876. PubMed ID: 30301411
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
11. Molecular Plasticity of Crystalline CK2α' Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity.
Lindenblatt D; Applegate V; Nickelsen A; Klußmann M; Neundorf I; Götz C; Jose J; Niefind K
J Med Chem; 2022 Jan; 65(2):1302-1312. PubMed ID: 34323071
[TBL] [Abstract][Full Text] [Related]
12. Rational Design of Coumarin Derivatives as CK2 Inhibitors by Improving the Interaction with the Hinge Region.
Zhang N; Chen WJ; Zhou Y; Zhao H; Zhong RG
Mol Inform; 2016 Jan; 35(1):15-8. PubMed ID: 27491649
[TBL] [Abstract][Full Text] [Related]
13. Structural and Mechanistic Basis of the Inhibitory Potency of Selected 2-Aminothiazole Compounds on Protein Kinase CK2.
Lindenblatt D; Nickelsen A; Applegate VM; Jose J; Niefind K
J Med Chem; 2020 Jul; 63(14):7766-7772. PubMed ID: 32589844
[TBL] [Abstract][Full Text] [Related]
14. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
[TBL] [Abstract][Full Text] [Related]
16. Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2.
Pietsch M; Viht K; Schnitzler A; Ekambaram R; Steinkrüger M; Enkvist E; Nienberg C; Nickelsen A; Lauwers M; Jose J; Uri A; Niefind K
Bioorg Chem; 2020 Mar; 96():103608. PubMed ID: 32058103
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.
Laudet B; Barette C; Dulery V; Renaudet O; Dumy P; Metz A; Prudent R; Deshiere A; Dideberg O; Filhol O; Cochet C
Biochem J; 2007 Dec; 408(3):363-73. PubMed ID: 17714077
[TBL] [Abstract][Full Text] [Related]
19. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
20. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]